]> C61.9 Prostate gland Note 1: Transitional cell (urothelial) carcinoma of the prostatic urethra is to be coded to primary site C68.0, Urethra, and assigned Collaborative Stage codes according to the urethra schema. Note 2: The 7th Edition AJCC stage group is derived not only from the T, N, and M categories but also from Site-Specific Factor 1 (PSA Lab Value) and Site-Specific Factor 8 or 10 (Gleason's Score). The specific Gleason's Score used is dependent upon the values of CS Extension - Clinical Extension, Site-Specific Factor 3 (CS Extension - Pathologic Extension) and CS Tumor Size/Ext Eval as shown in the Special Calculation Table for TNM 7 Invasive/Unknown Pathologic Extension Eval and Special Calculation Table for TNM 7 Non-Invasive Pathologic Extension. &generalsize; CS Extension - Clinical Extension Note 1: This field and CS Site-Specific Factor 3, CS Extension - Pathologic Extension, must both be coded, whether or not a prostatectomy was performed. Information from prostatectomy and autopsy is excluded from this field and coded only in CS Site-Specific Factor 3. Note 2: AJCC considers "in situ carcinoma of prostate gland" an impossible diagnosis. Any case so coded will be mapped to TX for AJCC stage and in situ Summary Stage. Note 4: Involvement of the prostatic urethra does not alter the extension code. Note 5: "Frozen pelvis" is a clinical term which means tumor extends to pelvic sidewall(s). In the absence of a more detailed statement of involvement, assign a description of frozen pelvis to code 600. Note 6: The mapping values for TNM, SS77, and SS2000 and the associated c, p, yp, or a indicator (staging basis) are assigned based on the values in CS Extension - Clinical Extension, CS Tumor Size/Ext Eval, and CS Site-Specific Factor 3 - Pathologic Extension. The calculation depends on whether clinical information or pathologic information takes precedence in a specific case. Note that for prostate, AJCC pathologic staging usually requires a prostatectomy. Pathologic staging information from a prostatectomy takes precedence except when neoadjuvant treatment has been given and clinical extension is either as extensive or more extensive than pathologic extension. The CS algorithm implements this logic as shown in the special calculation extra tables. Some combinations of codes may be errors. The CS algorithm will derive stage values if possible; a separate edit program may be required to identify errors for correction. Code Description TNM 7 Map TNM 6 Map SS77 Map SS2000 Map 000 In situ, intraepithelial, noninvasive TX TX IS IS 100 T1NOS T1NOS L L 130 T1a T1a L L 140 T1b T1b L L 150 T1c T1c L L 200 T2NOS T2NOS L L 210 T2a T2a L L 220 T2b T2b L L 230 T2c T2c L L 240 T2NOS T2NOS L L 300 T2NOS T2NOS L L 310 ERROR ERROR ERROR ERROR 330 ERROR ERROR ERROR ERROR 340 ERROR ERROR ERROR ERROR 410 T3NOS T3NOS RE RE 420 Unilateral extracapsular extension T3a T3a RE RE 430 Bilateral extracapsular extension T3a T3a RE RE 440 Microscopic bladder neck involvement T3a T4 RE RE 445 Stated as T3a with no other information on extension T3a T3a RE RE 450 T3b T3b RE RE 470 T3b T4 RE RE 490 T3NOS T3NOS RE RE 500 T4 T4 RE RE 510 T4 T4 RE RE 520 T4 T4 D RE 600 T4 T4 D D 700 T4 T4 D D 750 Stated as T4 with no other information on extension T4 T4 RE RE 950 No evidence of primary tumor T0 T0 U U 999 TX TX U U CS Tumor Size/Ext Eval Note 1: THE CODES FOR THIS ITEM FOR PROSTATE DIFFER FROM THE CODES USED FOR MOST OTHER SITES. Note 2: For this site, use this item to evaluate the coding of tumor size and extension as coded in both CS Extension - Clinical Extension AND Site-Specific Factor 3, Pathologic Extension. If prostatectomy was performed and the information is useful for staging assign CS Tumor Size/Ext Eval code 4. If autopsy is performed and the information is useful for staging assign CS Tumor Size/Ext Eval code 3 or 8. If prostatectomy or autopsy was performed but the information is not useful for staging, CS Tumor Size/Ext Eval should be assigned based on the information coded in CS Extension - Clinical Extension. Note 3: AJCC allows pathologic staging to be assigned on the basis of some biopsies without resection. According to the AJCC manual, "In general, total prostatoseminal-vesiculectomy, including regional node specimen, and histologic confirmation are required for pathologic T classification". Simple prostatectomy is acceptable for pathologic T classification when disease is confined to the prostate and margins are negative. Under certain circumstances, pathologic T classification can be determined with other means. "For example, (1) positive biopsy of the rectum permits a pT4 classification without prostatoseminal-vesiculectomy, and (2) a biopsy revealing carcinoma in extraprostatic soft tissue permits a pT3 classification, as does a biopsy revealing adenocarcinoma infiltrating the seminal vesicles." Note 4: For this site, the T category and its associated c, p, yp, or a indicator are assigned based on the values in CS Extension, CS Tumor Size/Ext Eval, and Site-Specific Factor 3. For details, see CS Extension - Clinical Extension Note 7 and the special calculation extra tables. Note 5: According to AJCC, staging basis for transurethral resection of prostate (TURP) is clinical and is recorded as CS Tumor Size/Ext Eval "1" (c). Note 6: For CS Extension - Clinical Extension codes 100 -150 without prostatectomy assign CS Tumor Size/Ext Eval code 1 as these extension codes are only proven by TURP or needle core biopsy. Note 7: For CS Extension - Clinical Extension codes 200 - 240 without prostatectomy assign CS Tumor Size/Ext Eval code 0 as these extension codes are based on physical examination and/or imaging only and NOT biopsy. Note 8: If the extension (CS Extension - Clinical Extension) prior to neoadjuvant therapy is as extensive or more extensive than the extension at prostatectomy (Site-Specific Factor 3 - Pathologic Extension), assign CS Tumor Size/Ext Eval code 5. Note 9: If the extension (CS Extension - Clinical Extension) prior to neoadjuvant therapy is less extensive than the extension at prostatectomy (Site-Specific Factor 3 - Pathologic Extension), assign CS Tumor Size/Ext Eval code 6. Code Description Staging Basis 0 c 1 c 2 p 3 p 4 p 5 c 6 yp 8 a 9 c CS Lymph Nodes Note: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in CS Mets at DX. Code Description TNM 7 Map TNM 6 Map SS77 Map SS2000 Map 000 No regional lymph node involvement N0 N0 NONE NONE 100 N1 N1 RN RN 800 Lymph nodes, NOS N1 N1 RN RN 999 NX NX U U &generalregnodeseval; &generalreglnpos; &generalreglnexam; CS Mets at DX Code Description TNM 7 Map TNM 6 Map SS77 Map SS2000 Map 00 No distant metastasis M0 M0 NONE NONE 11 M1a M1a RN D 12 M1a M1a D D 20 Stated as M1a with no other information on distant metastasis M1a M1a D D 30 Metastasis in bone(s) M1b M1b D D 35 M1b M1b D D 38 Stated as M1b with no other information on distant metastasis M1b M1b D D 40 M1c M1c D D 45 ERROR ERROR ERROR ERROR 50 M1c M1c D D 55 M1c M1c D D 58 M1c M1c D D 60 M1NOS M1NOS D D 99 M0 MX U U &commonmetsevalprostate; CS Site-Specific Factor 1 Prostatic Specific Antigen (PSA) Lab Value Note 1: PSA is used in conjunction with anatomic extent of disease and Gleason score to distinguish among stage I, stage IIA, and stage IIB for AJCC 7 staging. Note 2: The same laboratory test should be used to record information in CS Site-Specific Factors 1 and 2. Note 3: Record to the nearest tenth in nanograms/milliliter (ng/ml) the highest PSA lab value documented in the medical record prior to diagnostic biopsy of prostate and treatment. The lab value may be recorded in the lab report, history and physical, or clinical statement in the pathology report, etc. For example, code a PSA of 20.0 ng/ml as 200. A lab value expressed in micrograms per liter (ug/L) is equivalent to the same value expressed in nanograms per milliliter (ng/ml). See General Rules Part I, Section 2 under Prostate for further instructions on coding PSA lab value. Note 4: A discrepancy between the PSA documented in the lab report and the PSA documented by the clinician may arise due the clinician adjusting the PSA value. Certain medications for benign prostatic hypertrophy (BPH) decrease the PSA. Therefore, ONLY if there is documentation by a clinician within the medical record of an adjusted PSA value, record the adjusted value. The registrar does not adjust the PSA value based on BPH medication use. If there is no documentation by a clinician within the medical record of an adjusted PSA value, record the PSA value provided. The fact that an adjusted PSA value is being recorded should be documented in a text field. Code Description 000 001 002-979 980 98.0 ng/ml or greater 981-987 988 989 990 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 2 Prostatic Specific Antigen (PSA) Interpretation Note 1: Record the interpretation for the highest PSA lab value recorded in the medical record prior to diagnostic biopsy of prostate and treatment. This lab value may be recorded in the lab report, history and physical, or clinical statement in the pathology report. See General Rules Part I, Section 2 for further instructions on coding lab test interpretations. Note 2: The interpretation should be for the same laboratory test recorded in CS Site-Specific Factor 1. Code Description 000 010 Positive/elevated 020 Negative/normal; within normal limits 030 Borderline; undetermined whether positive or negative 080 988 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 CS Site-Specific Factor 3 CS Extension - Pathologic Extension Note 1: Include information from prostatectomy and autopsy in this field and not in CS Extension - Clinical Extension. Only use histologic information from prostatectomy, including simple prostatectomy with negative margins, and autopsy in this field. Information from biopsy of extraprostatic sites is coded in CS Extension - Clinical Extension; information from needle core biopsy of prostate is coded in CS Site-Specific Factor 14. Note 2: Code 970 if there is no prostatectomy performed within the first course of treatment. Note 3: Limit information in this field to first course of treatment in the absence of disease progression. Note 4: AJCC considers "in situ carcinoma of prostate gland" an impossible diagnosis. Any case so coded is mapped to TX for AJCC stage and in situ Summary Stage. Note 5: When prostate cancer is an incidental finding during a prostatectomy for other reasons (for example, a cystoprostatectomy for bladder cancer), use the appropriate code for the extent of disease found (for example, involvement in one lobe, both lobes, or more). Note 6: When the apical margin, distal urethral margin, bladder base margin, or bladder neck margin is involved and there is no extracapsular extension, use code 400. Note 7: Involvement of the prostatic urethra does not alter the extension code. Note 8: "Frozen pelvis" is a clinical term which means tumor extends to pelvic sidewall(s). In the absence of a more detailed statement of involvement, assign this to code 600. Note 9: For information regarding stage calculations, refer to CS Extension - Clinical Extension Note 6 and the special calculation extra tables. Code Description TNM 7 Map TNM 6 Map SS77 SS2000 000 In situ, intraepithelial, noninvasive TX TX IS IS 020 ERROR ERROR ERROR ERROR 021 ERROR ERROR ERROR ERROR 022 ERROR ERROR ERROR ERROR 023 ERROR ERROR ERROR ERROR 030 ERROR ERROR ERROR ERROR 031 ERROR ERROR ERROR ERROR 032 ERROR ERROR ERROR ERROR 033 ERROR ERROR ERROR ERROR 034 ERROR ERROR ERROR ERROR 040 ERROR ERROR ERROR ERROR 041 ERROR ERROR ERROR ERROR 042 ERROR ERROR ERROR ERROR 043 ERROR ERROR ERROR ERROR 045 ERROR ERROR ERROR ERROR 048 ERROR ERROR ERROR ERROR 050 ERROR ERROR ERROR ERROR 052 ERROR ERROR ERROR ERROR 060 ERROR ERROR ERROR ERROR 070 ERROR ERROR ERROR ERROR 095 ERROR ERROR ERROR ERROR 096 ERROR ERROR ERROR ERROR 097 ERROR ERROR ERROR ERROR 098 ERROR ERROR ERROR ERROR 099 ERROR ERROR ERROR ERROR 200 Involves one lobe/side, NOS T2NOS T2NOS L L 210 T2a T2a L L 220 T2b T2b L L 230 T2c T2c L L 300 T2NOS T2NOS L L 320 Invasion into (but not beyond) prostatic capsule T2NOS T2NOS L L 330 T2a T2a L L 340 T2b T2b L L 350 T2c T2c L L 400 No extracapsular extension but specific margins involved (see Note 6) T2NOS T2NOS L RE 402 T2a T2a L RE 404 T2b T2b L RE 406 T2c T2c L RE 410 T3a T3a RE RE 415 T3a T3a RE RE 420 Unilateral extracapsular extension T3a T3a RE RE 430 Bilateral extracapsular extension T3a T3a RE RE 480 Extracapsular extension and specific margins involved (see Note 6) T3a T3a RE RE 482 Microscopic bladder neck involvement T3a T4 RE RE 483 Stated as pT3a with no other information on pathologic extension T3a T3a RE RE 485 T3b T3b RE RE 490 T3b T4 RE RE 495 T3NOS T3NOS RE RE 500 T4 T4 RE RE 510 T4 T4 RE RE 520 T4 T4 D RE 600 T4 T4 D D 700 T4 T4 D D 750 Stated as pT4 with no other information on pathologic extension T4 T4 D D 950 No evidence of primary tumor T0 T0 U U 960 Unknown if prostatectomy done TX TX U U 970 No prostatectomy done within first course of treatment TX TX U U 980 Prostatectomy performed, but not considered first course of treatment, for example performed after disease progression TX TX U U 985 Autopsy performed but extension unknown TX TX U U 990 TX TX U U CS Site-Specific Factor 4 Prostate Apex Involvement (OBSOLETE: Prostatic Acid Phosphatase (PAP)) Note 1: This CS Site-Specific Factor is collected for cases diagnosed through 12/31/2009. It is not required by any standard setter for cases diagnosed 01/01/2010 forward; use code 988. Note 2: Apex involvement was considered in prostate stage classification in the SEER Historic Local/Regional/Distant staging system, although it is not a staging element in AJCC 6 or 7 staging. This item allows collection of information about the involvement of the prostate apex with cancer, both clinically and at prostatectomy, useful for long-term trend analysis of SEER data for prostate anatomic stage. Note 3: Cancers arising in the apex were localized, and cancers extending to the prostatic apex were regional in Historic staging. The code digits 3 and 4, described in Note 4, provide specific information about involvement of apex for Historic stage, while the code digit 2 indicates apex involvement but does not distinguish between arising in and extending to. Note 5: Code apex involvement if clearly documented in the medical record. Try to determine if the cancer has extended into the apex from another part of the prostate or has arisen in the apex. If apex involvement is unknown both clinically and pathologically, use code 550. Code Description 000 010 020 030 080 110 No involvement of prostatic apex clinically and on prostatectomy 120 130 140 150 210 220 230 240 250 310 320 330 340 350 410 420 430 440 450 510 520 530 540 550 988 999 CS Site-Specific Factor 5 OBSOLETE - Gleason's Primary Pattern and Secondary Pattern Value Note: This CS Site-Specific Factor is obsolete beginning with CS Version 2 (codes, code descriptions, and notes). Old data are retained during conversion, but new cases are not coded 000-099 or 000. Use only code 988 for this field for all cases entered in CS Version 2. OBSOLETE V0200 Note 2: Following AJCC guidelines for coding multiple Gleason's Scores in prostate cancer, if there is more than one primary and secondary pattern value, the value to be coded is the one based on the larger tumor specimen. Please note that this rule is not the same as the rule for coding grade. Code Description 000 011 012 013 014 015 019 021 022 023 024 025 029 031 032 033 034 035 039 041 042 043 044 045 049 051 052 053 054 055 059 099 988 Not applicable: Information not collected for this schema 999 CS Site-Specific Factor 6 OBSOLETE - Gleason's Score Note: This CS Site-Specific Factor is obsolete beginning with CS Version 2 (codes, code descriptions, and notes). Old data are retained during conversion, but new cases are not coded 000-010 or 999.. Use only code 988 for this field for all cases entered in CS Version 2. OBSOLETE V0200 Note 2: Record the Gleason's score based on the addition of the primary and secondary pattern. OBSOLETE V0200 Note 3: Following AJCC guidelines for coding multiple Gleason's Scores in prostate cancer, if there is more than one primary and secondary pattern value, the value to be coded is the one based on the larger tumor specimen. Please note that this rule is not the same as the rule for coding grade. Code Description 000 002-010 988 Not applicable: Information not collected for this schema 999 CS Site-Specific Factor 7 Gleason's Primary Pattern and Secondary Pattern Values on Needle Core Biopsy/Transurethral Resection of Prostate (TURP) Note 1: Code the Gleason's primary and secondary patterns from needle core biopsy or TURP only in this field. Note 4: If needle core biopsy and TURP are both performed, code the pattern that reflects the highest score. Note 5: If needle core biopsy and TURP are not performed, use code 998. If the Gleason's pattern and score are not documented on needle core biopsy or TURP, use code 999. Code Description 011 Primary pattern 1, secondary pattern 1 012 Primary pattern 1, secondary pattern 2 013 Primary pattern 1, secondary pattern 3 014 Primary pattern 1, secondary pattern 4 015 Primary pattern 1, secondary pattern 5 019 Primary pattern 1, secondary pattern unknown 021 Primary pattern 2, secondary pattern 1 022 Primary pattern 2, secondary pattern 2 023 Primary pattern 2, secondary pattern 3 024 Primary pattern 2, secondary pattern 4 025 Primary pattern 2, secondary pattern 5 029 Primary pattern 2, secondary pattern unknown 031 Primary pattern 3, secondary pattern 1 032 Primary pattern 3, secondary pattern 2 033 Primary pattern 3, secondary pattern 3 034 Primary pattern 3, secondary pattern 4 035 Primary pattern 3, secondary pattern 5 039 Primary pattern 3, secondary pattern unknown 041 Primary pattern 4, secondary pattern 1 042 Primary pattern 4, secondary pattern 2 043 Primary pattern 4, secondary pattern 3 044 Primary pattern 4, secondary pattern 4 045 Primary pattern 4, secondary pattern 5 049 Primary pattern 4, secondary pattern unknown 051 Primary pattern 5, secondary pattern 1 052 Primary pattern 5, secondary pattern 2 053 Primary pattern 5, secondary pattern 3 054 Primary pattern 5, secondary pattern 4 055 Primary pattern 5, secondary pattern 5 059 Primary pattern 5, secondary pattern unknown 099 Primary pattern unknown, secondary pattern unknown 988 998 No needle core biopsy/TURP performed 999 CS Site-Specific Factor 8 Gleason's Score on Needle Core Biopsy/Transurethral Resection of Prostate (TURP) Note 1: Code the Gleason's score from needle core biopsy or TURP only in this field. Note 3: Record the Gleason's score based on the addition of the primary and secondary patterns coded in CS Site-Specific Factor 7. Note 4: If needle core biopsy and TURP are not performed, assign code 998. If the Gleason's pattern and score are not documented on needle core biopsy or TURP, assign code 999. Code Description 002-010 Gleason's score 988 Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code 988 may result in an edit error.) 998 No needle core biopsy/TURP performed 999 CS Site-Specific Factor 9 Gleason's Primary Pattern and Secondary Pattern Values on Prostatectomy/Autopsy Note 1: Code the Gleason's primary and secondary patterns from prostatectomy or autopsy only in this field. Note 3: If prostatectomy and autopsy are not performed, assign code 998. If the Gleason's pattern and score are not documented on prostatectomy or autopsy, assign code 999. Note 4: If a tertiary pattern is documented on prostatectomy or autopsy, do not code in either CS Site-Specific Factor 9 or CS Site-Specific Factor 10. Record the tertiary pattern in CS Site-Specific Factor 11. Code Description 011 Primary pattern 1, secondary pattern 1 012 Primary pattern 1, secondary pattern 2 013 Primary pattern 1, secondary pattern 3 014 Primary pattern 1, secondary pattern 4 015 Primary pattern 1, secondary pattern 5 019 Primary pattern 1, secondary pattern unknown 021 Primary pattern 2, secondary pattern 1 022 Primary pattern 2, secondary pattern 2 023 Primary pattern 2, secondary pattern 3 024 Primary pattern 2, secondary pattern 4 025 Primary pattern 2, secondary pattern 5 029 Primary pattern 2, secondary pattern unknown 031 Primary pattern 3, secondary pattern 1 032 Primary pattern 3, secondary pattern 2 033 Primary pattern 3, secondary pattern 3 034 Primary pattern 3, secondary pattern 4 035 Primary pattern 3, secondary pattern 5 039 Primary pattern 3, secondary pattern unknown 041 Primary pattern 4, secondary pattern 1 042 Primary pattern 4, secondary pattern 2 043 Primary pattern 4, secondary pattern 3 044 Primary pattern 4, secondary pattern 4 045 Primary pattern 4, secondary pattern 5 049 Primary pattern 4, secondary pattern unknown 051 Primary pattern 5, secondary pattern 1 052 Primary pattern 5, secondary pattern 2 053 Primary pattern 5, secondary pattern 3 054 Primary pattern 5, secondary pattern 4 055 Primary pattern 5, secondary pattern 5 059 Primary pattern 5, secondary pattern unknown 099 Primary pattern unknown, secondary pattern unknown 988 998 No prostatectomy/autopsy performed 999 CS Site-Specific Factor 10 Gleason's Score on Prostatectomy/Autopsy Note 1: Code the Gleason's score from prostatectomy or autopsy only in this field. Note 3: Record the Gleason's score based on the addition of the primary and secondary patterns coded in CS Site-Specific Factor 9. Note 4: If prostatectomy and autopsy are not performed, assign code 998. If the Gleason's pattern and score are not documented on prostatectomy or autopsy, assign code 999. Note 5: If a tertiary pattern is documented on prostatectomy or autopsy, do not code in either CS Site-Specific Factor 9 or CS Site-Specific Factor 10. Record the tertiary pattern in CS Site-Specific Factor 11. Code Description 002-010 988 Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code 988 may result in an edit error.) 998 No prostatectomy/autopsy performed 999 CS Site-Specific Factor 11 Gleason's Tertiary Pattern Value on Prostatectomy/Autopsy Note 1: If present, a high tertiary Gleason's pattern appears to be an indication for a worse outcome. Note 2: Record the tertiary pattern documented on prostatectomy or autopsy only. If a tertiary pattern is documented on needle core biopsy or transurethral resection of prostate (TURP), it should be disregarded. Do not code the tertiary pattern on prostatectomy or autopsy in CS Site-Specific Factor 9 or CS Site-Specific Factor 10. Code Description 010 Tertiary pattern 1 020 Tertiary pattern 2 030 Tertiary pattern 3 040 Tertiary pattern 4 050 Tertiary pattern 5 988 998 No prostatectomy/autopsy performed 999 CS Site-Specific Factor 12 Number of Cores Positive Note 1: Record the number of prostate core biopsies positive for cancer documented in the pathology report. Do not make assumptions on the number of cores positive based on the number of anatomic locations biopsied because often several cores are submitted per site. Fragments are not synonymous with cores and are not counted as cores unless the pathologist has included the fragments in the core count. If the number of cores positive is not specifically documented, code 991. Note 2: If multiple needle core biopsy procedures are performed during the initial diagnostic workup, do not add together the positive cores from the separate procedures. Record the number of cores positive for cancer from the procedure with the highest number of cores positive. Note 3: Transperineal template-guided saturation biopsy (TTSB) is a stereotactic prostate biopsy technique that typically produces 30 to 80 core biopsies. This is an alternative biopsy technique used for some high risk patients including men with persistently elevated PSA, those who have atypia on prior prostate biopsies, or men with biopsies showing high grade prostatic intraepithelial neoplasia (PIN). Code Description 000 All examined cores negative 001-024 025 026-100 101 101 or more cores positive 988 991 Biopsy cores positive, number unknown 995 998 No needle core biopsy performed 999 CS Site-Specific Factor 13 Number of Cores Examined Note 1: Record the number of prostate core biopsies examined for cancer documented in the pathology report. Do not make assumptions on the number of cores examined based on the number of anatomic locations biopsied because often several cores are submitted per site. Fragments are not synonymous with cores and are not counted as cores unless the pathologist has included the fragments in the core count. If the number of cores examined is not specifically documented, code 991. Note 2: If multiple needle core biopsy procedures are performed during the initial diagnostic workup, do not add together the cores examined from the separate procedures. Record the number of cores examined from the procedure with the highest number of cores positive, the same procedure used to record CS Site-Specific Factor 12. Note 3: Transperineal template-guided saturation biopsy (TTSB) is a stereotactic prostate biopsy technique that typically produces 30 to 80 core biopsies. This is an alternative biopsy technique used for some high risk patients including men with persistently elevated PSA, those who have atypia on prior prostate biopsies, or men with biopsies showing high grade prostatic intraepithelial neoplasia (PIN). Code Description 001-024 025 026-100 101 101 or more cores examined 988 991 Biopsy cores examined, number unknown 995 998 No needle core biopsy performed 999 CS Site-Specific Factor 14 Needle Core Biopsy Findings Note 1: Record the findings of needle core biopsy as documented in the medical record. Note 2: If multiple needle core biopsy procedures are performed during the initial diagnostic workup, record the most extensive findings from all biopsy procedures. Code 050 takes precedence over codes 010, 020, and 030. Code Description 000 Negative needle core biopsy findings 010 Positive needle core biopsy findings in one lobe/side 020 Positive needle core biopsy findings in both lobes/sides 030 Positive needle core biopsy findings, location (lobes/sides) not stated 050 Positive needle core biopsy findings beyond prostate 988 998 No needle core biopsy performed 999 CS Site-Specific Factor 15 Clinical Staging Procedures Performed Note 1: Investigators are interested in determining the clinical staging procedures used to assign tumors to the T1c category. Procedures used in clinical staging include digital rectal examination (DRE) and imaging techniques of the prostate. Imaging includes transrectal ultrasound (TRUS) and endorectal coil magnetic resonance imaging (erMRI). Note 2: Record the procedure(s) used in clinical staging for all T categories regardless of positive or negative findings. Record TRUS-guided biopsy as imaging. Note 3: Clinical procedures performed after needle core biopsy or any surgical procedure of the prostate are not included in this field. Code Description 000 No DRE and no imaging performed 010 DRE only performed, imaging not performed or unknown if performed 020 Imaging only performed, DRE not performed or unknown if performed 030 988 999 ¬appnewssf16; ¬appnewssf17; ¬appnewssf18; ¬appnewssf19; ¬appnewssf20; ¬appnewssf21; ¬appnewssf22; ¬appnewssf23; ¬appnewssf24; ¬appnewssf25; &commonhistinclusionprostate; Histology Exclusion Table AJCC 6th ed. Note: Histology codes listed in this Histology Exclusion Table for this site are codes that are not TNM staged according to the AJCC 6th Edition Cancer Staging Manual. When a case is coded in Collaborative Staging and the histology is on the exclusion list, TNM will not be calculated but SEER algorithm Summary Stage 1977 and 2000 can be assigned. For these cases, displayed results will be "T NA N NA M NA and Stage Group NA". Code Description 8120/0 Transitional cell papilloma, benign 8120/1 Urothelial papilloma, NOS 8120/2 Transitional cell carcinoma in situ 8120/3 Transitional cell carcinoma, NOS 8121/0 Schneiderian papilloma, NOS (C30.0, C31._) 8121/1 Transitional cell papilloma, inverted, NOS 8121/3 Schneiderian carcinoma (C30.0, C31._) 8122/3 Transitional cell carcinoma, spindle cell 8123/3 Basaloid carcinoma 8124/3 Cloacogenic carcinoma (C21.2) 8130/1 Papillary transitional cell neoplasm of low malignant potential (C67._) 8130/2 Papillary transitional cell carcinoma, non-invasive (C67._) 8130/3 Papillary transitional cell carcinoma (C67._) 8131/3 Transitional cell carcinoma, micropapillary (C67._) 8240/1 Carcinoid tumor of uncertain malignant potential 8240/3 Carcinoid tumor, NOS (except of appendix M-8240/1) 8241/3 Enterochromaffin cell carcinoid 8242/1 Enterochromaffin-like cell carcinoid, NOS 8242/3 Enterochromaffin-like cell tumor, malignant 8243/3 Goblet cell carcinoid 8248/1 Apudoma 8680/0 Paraganglioma, benign 8680/1 Paraganglioma, NOS 8680/3 Paraganglioma, malignant 8681/1 Sympathetic paraganglioma 8682/1 Parasympathetic paraganglioma 8683/0 Gangliocytic paraganglioma (C17.0) 8690/1 Glomus jugulare tumor, NOS (C75.5) 8691/1 Aortic body tumor (C75.5) 8692/1 Carotid body tumor (C75.4) 8693/1 Extra-adrenal paraganglioma, NOS 8693/3 Extra-adrenal paraganglioma, malignant 8700/0 Pheochromocytoma, NOS (C74.1) 8700/3 Pheochromocytoma, malignant (C74.1) 8710/3 Glomangiosarcoma 8711/0 Glomus tumor, NOS 8711/3 Glomus tumor, malignant 8712/0 Glomangioma 8713/0 Glomangiomyoma 8720/0 Pigmented nevus, NOS (C44._) 8720/2 Melanoma in situ 8720/3 Malignant melanoma, NOS (except juvenile melanoma M-8770/0) 8721/3 Nodular melanoma (C44._) 8722/0 Balloon cell nevus (C44._) 8722/3 Balloon cell melanoma (C44._) 8723/0 Halo nevus (C44._) 8723/3 Malignant melanoma, regressing (C44._) 8725/0 Neuronevus (C44._) 8726/0 Magnocellular nevus (C69.4) 8727/0 Dysplastic nevus (C44._) 8728/0 Diffuse melanocytosis (C70.9) 8728/1 Meningeal melanocytoma (C70.9) 8728/3 Meningeal melanomatosis (C70.9) 8730/0 Nonpigmented nevus (C44._) 8730/3 Amelanotic melanoma (C44._) 8740/0 Junctional nevus, NOS (C44._) 8740/3 Malignant melanoma in junctional nevus (C44._) 8741/2 Precancerous melanosis, NOS (C44._) 8741/3 Malignant melanoma in precancerous melanosis (C44._) 8742/2 Lentigo maligna (C44._) 8742/3 Lentigo maligna melanoma (C44._) 8743/3 Superficial spreading melanoma (C44._) 8744/3 Acral lentiginous melanoma, malignant (C44._) 8745/3 Desmoplastic melanoma, malignant (C44._) 8746/3 Mucosal lentiginous melanoma 8750/0 Intradermal nevus (C44._) 8760/0 Compound nevus (C44._) 8761/0 Small congenital nevus (C44._) 8761/1 Giant pigmented nevus, NOS (C44._) 8761/3 Malignant melanoma in giant pigmented nevus (C44._) 8762/1 Proliferative dermal lesion in congenital nevus (C44._) 8770/0 Epithelioid and spindle cell nevus (C44._) 8770/3 Mixed epithelioid and spindle cell melanoma 8771/0 Epithelioid cell nevus (C44._) 8771/3 Epithelioid cell melanoma 8772/0 Spindle cell nevus, NOS (C44._) 8772/3 Spindle cell melanoma, NOS 8773/3 Spindle cell melanoma, type A (C69._) 8774/3 Spindle cell melanoma, type B (C69._) 8780/0 Blue nevus, NOS (C44._) 8780/3 Blue nevus, malignant (C44._) 8790/0 Cellular blue nevus (C44._) 8800/0 Soft tissue tumor, benign 8800/3 Sarcoma, NOS 8800/9 Sarcomatosis, NOS 8801/3 Spindle cell sarcoma 8802/3 Giant cell sarcoma (except of bone M-9250/3) 8803/3 Small cell sarcoma 8804/3 Epithelioid sarcoma 8805/3 Undifferentiated sarcoma 8806/3 Desmoplastic small round cell tumor 8810/0 Fibroma, NOS 8810/1 Cellular fibroma (C56.9) 8810/3 Fibrosarcoma, NOS 8811/0 Fibromyxoma 8811/3 Fibromyxosarcoma 8812/0 Periosteal fibroma (C40._, C41._) 8812/3 Periosteal fibrosarcoma (C40._, C41._) 8813/0 Fascial fibroma 8813/3 Fascial fibrosarcoma 8814/3 Infantile fibrosarcoma 8815/0 Solitary fibrous tumor 8815/3 Solitary fibrous tumor, malignant 8820/0 Elastofibroma 8821/1 Aggressive fibromatosis 8822/1 Abdominal fibromatosis 8823/0 Desmoplastic fibroma 8824/0 Myofibroma 8824/1 Myofibromatosis 8825/0 Myofibroblastoma 8825/1 Myofibroblastic tumor, NOS 8826/0 Angiomyofibroblastoma 8827/1 Myofibroblastic tumor, peribronchial (C34._) 8830/0 Benign fibrous histiocytoma 8830/1 Atypical fibrous histiocytoma 8830/3 Malignant fibrous histiocytoma 8831/0 Histiocytoma, NOS 8832/0 Dermatofibroma, NOS (C44._) 8832/3 Dermatofibrosarcoma, NOS (C44._) 8833/3 Pigmented dermatofibrosarcoma protuberans (C44._) 8834/1 Giant cell fibroblastoma 8835/1 Plexiform fibrohistiocytic tumor 8836/1 Angiomatoid fibrous histiocytoma 8840/0 Myxoma, NOS 8840/3 Myxosarcoma 8841/1 Angiomyxoma 8842/0 Ossifying fibromyxoid tumor 8850/0 Lipoma, NOS 8850/1 Atypical lipoma 8850/3 Liposarcoma, NOS 8851/0 Fibrolipoma 8851/3 Liposarcoma, well differentiated 8852/0 Fibromyxolipoma 8852/3 Myxoid liposarcoma 8853/3 Round cell liposarcoma 8854/0 Pleomorphic lipoma 8854/3 Pleomorphic liposarcoma 8855/3 Mixed liposarcoma 8856/0 Intramuscular lipoma 8857/0 Spindle cell lipoma 8857/3 Fibroblastic liposarcoma 8858/3 Dedifferentiated liposarcoma 8860/0 Angiomyolipoma 8861/0 Angiolipoma, NOS 8862/0 Chondroid lipoma 8870/0 Myelolipoma 8880/0 Hibernoma 8881/0 Lipoblastomatosis 8890/0 Leiomyoma, NOS 8890/1 Leiomyomatosis, NOS 8890/3 Leiomyosarcoma, NOS 8891/0 Epithelioid leiomyoma 8891/3 Epithelioid leiomyosarcoma 8892/0 Cellular leiomyoma 8893/0 Bizarre leiomyoma 8894/0 Angiomyoma 8894/3 Angiomyosarcoma 8895/0 Myoma 8895/3 Myosarcoma 8896/3 Myxoid leiomyosarcoma 8897/1 Smooth muscle tumor of uncertain malignant potential 8898/1 Metastasizing leiomyoma 8900/0 Rhabdomyoma, NOS 8900/3 Rhabdomyosarcoma, NOS 8901/3 Pleomorphic rhabdomyosarcoma, adult type 8902/3 Mixed type rhabdomyosarcoma 8903/0 Fetal rhabdomyoma 8904/0 Adult rhabdomyoma 8905/0 Genital rhabdomyoma (C51._, C52.9) 8910/3 Embryonal rhabdomyosarcoma, NOS 8912/3 Spindle cell rhabdomyosarcoma 8920/3 Alveolar rhabdomyosarcoma 8921/3 Rhabdomyosarcoma with ganglionic differentiation 8930/0 Endometrial stromal nodule (C54.1) 8930/3 Endometrial stromal sarcoma, NOS (C54.1) 8931/3 Endometrial stromal sarcoma, low grade (C54.1) 8932/0 Adenomyoma 8933/3 Adenosarcoma 8934/3 Carcinofibroma 8935/0 Stromal tumor, benign 8935/1 Stromal tumor, NOS 8935/3 Stromal sarcoma, NOS 8936/0 Gastrointestinal stromal tumor, benign 8936/1 Gastrointestinal stromal tumor, NOS 8936/3 Gastrointestinal stromal sarcoma 8950/3 Mullerian mixed tumor (C54._) 8951/3 Mesodermal mixed tumor 8959/0 Benign cystic nephroma (C64.9) 8959/1 Cystic partially differentiated nephroblastoma (C64.9) 8959/3 Malignant cystic nephroma (C64.9) 8960/1 Mesoblastic nephroma 8960/3 Nephroblastoma, NOS (C64.9) 8963/3 Malignant rhabdoid tumor 8964/3 Clear cell sarcoma of kidney (C64.9) 8965/0 Nephrogenic adenofibroma (C64.9) 8966/0 Renomedullary interstitial cell tumor (C64.9) 8967/0 Ossifying renal tumor (C64.9) 8970/3 Hepatoblastoma (C22.0) 8971/3 Pancreatoblastoma (C25._) 8972/3 Pulmonary blastoma (C34._) 8973/3 Pleuropulmonary blastoma 8974/1 Sialoblastoma 8980/3 Carcinosarcoma, NOS 8981/3 Carcinosarcoma, embryonal 8982/0 Myoepithelioma 8982/3 Malignant myoepithelioma 8983/0 Adenomyoepithelioma (C50._) 8990/0 Mesenchymoma, benign 8990/1 Mesenchymoma, NOS 8990/3 Mesenchymoma, malignant 8991/3 Embryonal sarcoma 9000/0 Brenner tumor, NOS (C56.9) 9000/1 Brenner tumor, borderline malignancy (C56.9) 9000/3 Brenner tumor, malignant (C56.9) 9010/0 Fibroadenoma, NOS (C50._) 9011/0 Intracanalicular fibroadenoma (C50._) 9012/0 Pericanalicular fibroadenoma (C50._) 9013/0 Adenofibroma, NOS 9014/0 Serous adenofibroma, NOS 9014/1 Serous adenofibroma of borderline malignancy 9014/3 Serous adenocarcinofibroma 9015/0 Mucinous adenofibroma, NOS 9015/1 Mucinous adenofibroma of borderline malignancy 9015/3 Mucinous adenocarcinofibroma 9016/0 Giant fibroadenoma (C50._) 9020/0 Phyllodes tumor, benign (C50._) 9020/1 Phyllodes tumor, borderline (C50._) 9020/3 Phyllodes tumor, malignant (C50._) 9030/0 Juvenile fibroadenoma (C50._) 9040/0 Synovioma, benign 9040/3 Synovial sarcoma, NOS 9041/3 Synovial sarcoma, spindle cell 9042/3 Synovial sarcoma, epithelioid cell 9043/3 Synovial sarcoma, biphasic 9044/3 Clear cell sarcoma, NOS (except of kidney M-8964/3) 9050/0 Mesothelioma, benign 9050/3 Mesothelioma, malignant 9051/0 Fibrous mesothelioma, benign 9051/3 Fibrous mesothelioma, malignant 9052/0 Epithelioid mesothelioma, benign 9052/3 Epithelioid mesothelioma, malignant 9053/3 Mesothelioma, biphasic, malignant 9054/0 Adenomatoid tumor, NOS 9055/0 Multicystic mesothelioma, benign 9055/1 Cystic mesothelioma, NOS (C48._) 9060/3 Dysgerminoma 9061/3 Seminoma, NOS (C62._) 9062/3 Seminoma, anaplastic (C62._) 9063/3 Spermatocytic seminoma (C62._) 9064/2 Intratubular malignant germ cells (C62._) 9064/3 Germinoma 9065/3 Germ cell tumor, nonseminomatous (C62._) 9070/3 Embryonal carcinoma, NOS 9071/3 Yolk sac tumor 9072/3 Polyembryoma 9073/1 Gonadoblastoma 9080/0 Teratoma, benign 9080/1 Teratoma, NOS 9080/3 Teratoma, malignant, NOS 9081/3 Teratocarcinoma 9082/3 Malignant teratoma, undifferentiated 9083/3 Malignant teratoma, intermediate 9084/0 Dermoid cyst, NOS 9084/3 Teratoma with malignant transformation 9085/3 Mixed germ cell tumor 9090/0 Struma ovarii, NOS (C56.9) 9090/3 Struma ovarii, malignant (C56.9) 9091/1 Strumal carcinoid (C56.9) 9100/0 Hydatidiform mole, NOS (C58.9) 9100/1 Invasive hydatidiform mole (C58.9) 9100/3 Choriocarcinoma, NOS 9101/3 Choriocarcinoma combined with other germ cell elements 9102/3 Malignant teratoma, trophoblastic 9103/0 Partial hydatidiform mole (C58.9) 9104/1 Placental site trophoblastic tumor (C58.9) 9105/3 Trophoblastic tumor, epithelioid 9110/0 Mesonephroma, benign 9110/1 Mesonephric tumor, NOS 9110/3 Mesonephroma, malignant 9120/0 Hemangioma, NOS 9120/3 Hemangiosarcoma 9121/0 Cavernous hemangioma 9122/0 Venous hemangioma 9123/0 Racemose hemangioma 9124/3 Kupffer cell sarcoma (C22.0) 9125/0 Epithelioid hemangioma 9130/0 Hemangioendothelioma, benign 9130/1 Hemangioendothelioma, NOS 9130/3 Hemangioendothelioma, malignant 9131/0 Capillary hemangioma 9132/0 Intramuscular hemangioma 9133/1 Epithelioid hemangioendothelioma, NOS 9133/3 Epithelioid hemangioendothelioma, malignant 9135/1 Endovascular papillary angioendothelioma 9136/1 Spindle cell hemangioendothelioma 9140/3 Kaposi sarcoma 9141/0 Angiokeratoma 9142/0 Verrucous keratotic hemangioma 9150/0 Hemangiopericytoma, benign 9150/1 Hemangiopericytoma, NOS 9150/3 Hemangiopericytoma, malignant 9160/0 Angiofibroma, NOS 9161/0 Acquired tufted hemangioma 9161/1 Hemangioblastoma 9170/0 Lymphangioma, NOS 9170/3 Lymphangiosarcoma 9171/0 Capillary lymphangioma 9172/0 Cavernous lymphangioma 9173/0 Cystic lymphangioma 9174/0 Lymphangiomyoma 9174/1 Lymphangiomyomatosis 9175/0 Hemolymphangioma 9180/0 Osteoma, NOS (C40._, C41._) 9180/3 Osteosarcoma, NOS (C40._, C41._) 9181/3 Chondroblastic osteosarcoma (C40._, C41._) 9182/3 Fibroblastic osteosarcoma (C40._, C41._) 9183/3 Telangiectatic osteosarcoma (C40._, C41._) 9184/3 Osteosarcoma in Paget disease of bone (C40._, C41._) 9185/3 Small cell osteosarcoma (C40._, C41._) 9186/3 Central osteosarcoma (C40._, C41._) 9187/3 Intraosseous well differentiated osteosarcoma (C40._, C41._) 9191/0 Osteoid osteoma, NOS (C40._, C41._) 9192/3 Parosteal osteosarcoma (C40._, C41._) 9193/3 Periosteal osteosarcoma (C40._, C41._) 9194/3 High grade surface osteosarcoma (C40._, C41._) 9195/3 Intracortical osteosarcoma (C40._, C41._) 9200/0 Osteoblastoma, NOS (C40._, C41._) 9200/1 Aggressive osteoblastoma (C40._, C41._) 9210/0 Osteochondroma (C40._, C41._) 9210/1 Osteochondromatosis, NOS (C40._, C41._) 9220/0 Chondroma, NOS (C40._, C41._) 9220/1 Chondromatosis, NOS 9220/3 Chondrosarcoma, NOS (C40._, C41._) 9221/0 Juxtacortical chondroma (C40._, C41._) 9221/3 Juxtacortical chondrosarcoma (C40._, C41._) 9230/0 Chondroblastoma, NOS (C40._, C41._) 9230/3 Chondroblastoma, malignant (C40._, C41._) 9231/3 Myxoid chondrosarcoma 9240/3 Mesenchymal chondrosarcoma 9241/0 Chondromyxoid fibroma (C40._, C41._) 9242/3 Clear cell chondrosarcoma (C40._, C41._) 9243/3 Dedifferentiated chondrosarcoma (C40._, C41._) 9250/1 Giant cell tumor of bone, NOS (C40._, C41._) 9250/3 Giant cell tumor of bone, malignant (C40._, C41._) 9251/1 Giant cell tumor of soft parts, NOS 9251/3 Malignant giant cell tumor of soft parts 9252/0 Tenosynovial giant cell tumor (C49._) 9252/3 Malignant tenosynovial giant cell tumor (C49._) 9260/3 Ewing sarcoma 9261/3 Adamantinoma of long bones (C40._) 9262/0 Ossifying fibroma 9270/0 Odontogenic tumor, benign 9270/1 Odontogenic tumor, NOS 9270/3 Odontogenic tumor, malignant 9271/0 Ameloblastic fibrodentinoma 9272/0 Cementoma, NOS 9273/0 Cementoblastoma, benign 9274/0 Cementifying fibroma 9275/0 Gigantiform cementoma 9280/0 Odontoma, NOS 9281/0 Compound odontoma 9282/0 Complex odontoma 9290/0 Ameloblastic fibro-odontoma 9290/3 Ameloblastic odontosarcoma 9300/0 Adenomatoid odontogenic tumor 9301/0 Calcifying odontogenic cyst 9302/0 Odontogenic ghost cell tumor 9310/0 Ameloblastoma, NOS 9310/3 Ameloblastoma, malignant 9311/0 Odontoameloblastoma 9312/0 Squamous odontogenic tumor 9320/0 Odontogenic myxoma 9321/0 Central odontogenic fibroma 9322/0 Peripheral odontogenic fibroma 9330/0 Ameloblastic fibroma 9330/3 Ameloblastic fibrosarcoma 9340/0 Calcifying epithelial odontogenic tumor 9341/1 Clear cell odontogenic tumor 9342/3 Odontogenic carcinosarcoma 9350/1 Craniopharyngioma (C75.2) 9351/1 Craniopharyngioma, adamantinomatous (C75.2) 9352/1 Craniopharyngioma, papillary (C75.2) 9360/1 Pinealoma (C75.3) 9361/1 Pineocytoma (C75.3) 9362/3 Pineoblastoma (C75.3) 9363/0 Melanotic neuroectodermal tumor 9364/3 Peripheral neuroectodermal tumor 9365/3 Askin tumor 9370/3 Chordoma, NOS 9371/3 Chondroid chordoma 9372/3 Dedifferentiated chordoma 9373/0 Parachordoma 9380/3 Glioma, malignant (C71._) 9381/3 Gliomatosis cerebri (C71._) 9382/3 Mixed glioma (C71._) 9383/1 Subependymoma (C71._) 9384/1 Subependymal giant cell astrocytoma (C71._) 9390/0 Choroid plexus papilloma, NOS (C71.5) 9390/1 Atypical choroid plexus papilloma (C71.5) 9390/3 Choroid plexus carcinoma (C71.5) 9391/3 Ependymoma, NOS (C71._) 9392/3 Ependymoma, anaplastic (C71._) 9393/3 Papillary ependymoma (C71._) 9394/1 Myxopapillary ependymoma (C72.0) 9400/3 Astrocytoma, NOS (C71._) 9401/3 Astrocytoma, anaplastic (C71._) 9410/3 Protoplasmic astrocytoma (C71._) 9411/3 Gemistocytic astrocytoma (C71._) 9412/1 Desmoplastic infantile astrocytoma (C71._) 9413/0 Dysembryoplastic neuroepithelial tumor 9420/3 Fibrillary astrocytoma (C71._) 9421/1 Pilocytic astrocytoma (C71._) 9423/3 Polar spongioblastoma (C71._) 9424/3 Pleomorphic xanthoastrocytoma (C71._) 9430/3 Astroblastoma (C71._) 9440/3 Glioblastoma, NOS (C71._) 9441/3 Giant cell glioblastoma (C71._) 9442/1 Gliofibroma (C71._) 9442/3 Gliosarcoma (C71._) 9444/1 Chordoid glioma (C71._) 9450/3 Oligodendroglioma, NOS (C71._) 9451/3 Oligodendroglioma, anaplastic (C71._) 9460/3 Oligodendroblastoma (C71._) [obs] 9470/3 Medulloblastoma, NOS (C71.6) 9471/3 Desmoplastic nodular medulloblastoma (C71.6) 9472/3 Medullomyoblastoma (C71.6) 9473/3 Primitive neuroectodermal tumor, NOS 9474/3 Large cell medulloblastoma (C71.6) 9480/3 Cerebellar sarcoma, NOS (C71.6) [obs] 9490/0 Ganglioneuroma 9490/3 Ganglioneuroblastoma 9491/0 Ganglioneuromatosis 9492/0 Gangliocytoma 9493/0 Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos) (C71.6) 9500/3 Neuroblastoma, NOS 9501/0 Medulloepithelioma, benign (C69.4) 9501/3 Medulloepithelioma, NOS 9502/0 Teratoid medulloepithelioma, benign (C69.4) 9502/3 Teratoid medulloepithelioma 9503/3 Neuroepithelioma, NOS 9504/3 Spongioneuroblastoma 9505/1 Ganglioglioma, NOS 9505/3 Ganglioglioma, anaplastic 9506/1 Central neurocytoma 9507/0 Pacinian tumor 9508/3 Atypical teratoid/rhabdoid tumor (C71._) 9510/0 Retinocytoma (C69.2) 9510/3 Retinoblastoma, NOS (C69.2) 9511/3 Retinoblastoma, differentiated (C69.2) 9512/3 Retinoblastoma, undifferentiated (C69.2) 9513/3 Retinoblastoma, diffuse (C69.2) 9514/1 Retinoblastoma, spontaneously regressed (C69.2) 9520/3 Olfactory neurogenic tumor 9521/3 Olfactory neurocytoma (C30.0) 9522/3 Olfactory neuroblastoma (C30.0) 9523/3 Olfactory neuroepithelioma (C30.0) 9530/0 Meningioma, NOS 9530/1 Meningiomatosis, NOS 9530/3 Meningioma, malignant 9531/0 Meningothelial meningioma 9532/0 Fibrous meningioma 9533/0 Psammomatous meningioma 9534/0 Angiomatous meningioma 9535/0 Hemangioblastic meningioma [obs] 9537/0 Transitional meningioma 9538/1 Clear cell meningioma 9538/3 Papillary meningioma 9539/1 Atypical meningioma 9539/3 Meningeal sarcomatosis 9540/0 Neurofibroma, NOS 9540/1 Neurofibromatosis, NOS 9540/3 Malignant peripheral nerve sheath tumor 9541/0 Melanotic neurofibroma 9550/0 Plexiform neurofibroma 9560/0 Neurilemoma, NOS 9560/1 Neurinomatosis 9560/3 Neurilemoma, malignant [obs] 9561/3 Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation 9562/0 Neurothekeoma 9570/0 Neuroma, NOS 9571/0 Perineurioma, NOS 9571/3 Perineurioma, malignant 9580/0 Granular cell tumor, NOS 9580/3 Granular cell tumor, malignant 9581/3 Alveolar soft part sarcoma 9582/0 Granular cell tumor of the sellar region (C75.1) 9590/3 Malignant lymphoma, NOS 9591/3 Malignant lymphoma, non-Hodgkin, NOS 9596/3 Composite Hodgkin and non-Hodgkin lymphoma 9650/3 Hodgkin lymphoma, NOS 9651/3 Hodgkin lymphoma, lymphocyte-rich 9652/3 Hodgkin lymphoma, mixed cellularity, NOS 9653/3 Hodgkin lymphoma, lymphocyte depletion, NOS 9654/3 Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis 9655/3 Hodgkin lymphoma, lymphocyte depletion, reticular 9659/3 Hodgkin lymphoma, nodular lymphocyte predominance 9661/3 Hodgkin granuloma [obs] 9662/3 Hodgkin sarcoma [obs] 9663/3 Hodgkin lymphoma, nodular sclerosis, NOS 9664/3 Hodgkin lymphoma, nodular sclerosis, cellular phase 9665/3 Hodgkin lymphoma, nodular sclerosis, grade 1 9667/3 Hodgkin lymphoma, nodular sclerosis, grade 2 9670/3 Malignant lymphoma, small B lymphocytic, NOS (see also M-9823/3) 9671/3 Malignant lymphoma, lymphoplasmacytic (see also M-9761/3) 9673/3 Mantle cell lymphoma 9675/3 Malignant lymphoma, mixed small and large cell, diffuse [obs] (see also M-9690/3) 9678/3 Primary effusion lymphoma 9679/3 Mediastinal large B-cell lymphoma (C38.3) 9680/3 Malignant lymphoma, large B-cell, diffuse, NOS 9684/3 Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS 9687/3 Burkitt lymphoma, NOS (see also M-9826/3) 9689/3 Splenic marginal zone B-cell lymphoma (C42.2) 9690/3 Follicular lymphoma, NOS (see also M-9675/3) 9691/3 Follicular lymphoma, grade 2 9695/3 Follicular lymphoma, grade 1 9698/3 Follicular lymphoma, grade 3 9699/3 Marginal zone B-cell lymphoma, NOS 9700/3 Mycosis fungoides (C44._) 9701/3 Sezary syndrome 9702/3 Mature T-cell lymphoma, NOS 9705/3 Angioimmunoblastic T-cell lymphoma 9708/3 Subcutaneous panniculitis-like T-cell lymphoma 9709/3 Cutaneous T-cell lymphoma, NOS (C44._) 9714/3 Anaplastic large cell lymphoma, T cell and Null cell type 9716/3 Hepatosplenic ?? (gamma-delta) cell lymphoma 9717/3 Intestinal T-cell lymphoma 9718/3 Primary cutaneous CD30+ T-cell lymphoproliferative disorder (C44._) 9719/3 NK/T-cell lymphoma, nasal and nasal-type 9727/3 Precursor cell lymphoblastic lymphoma, NOS (see also M-9835/3) 9728/3 Precursor B-cell lymphoblastic lymphoma (see also M-9836/3) 9729/3 Precursor T-cell lymphoblastic lymphoma (see also M-9837/3) 9731/3 Plasmacytoma, NOS 9732/3 Multiple myeloma (C42.1) 9733/3 Plasma cell leukemia (C42.1) 9734/3 Plasmacytoma, extramedullary (not occurring in bone) 9740/1 Mastocytoma, NOS 9740/3 Mast cell sarcoma 9741/3 Malignant mastocytosis 9742/3 Mast cell leukemia (C42.1) 9750/3 Malignant histiocytosis 9751/1 Langerhans cell histiocytosis, NOS 9752/1 Langerhans cell histiocytosis, unifocal 9753/1 Langerhans cell histiocytosis, multifocal 9754/3 Langerhans cell histiocytosis, disseminated 9755/3 Histiocytic sarcoma 9756/3 Langerhans cell sarcoma 9757/3 Interdigitating dendritic cell sarcoma 9758/3 Follicular dendritic cell sarcoma 9760/3 Immunoproliferative disease, NOS 9761/3 Waldenstrom macroglobulinemia (C42.0) (see also M-9671/3) 9762/3 Heavy chain disease, NOS 9764/3 Immunoproliferative small intestinal disease (C17._) 9765/1 Monoclonal gammopathy of undetermined significance 9766/1 Angiocentric immunoproliferative lesion 9767/1 Angioimmunoblastic lymphadenopathy 9768/1 T-gamma lymphoproliferative disease 9769/1 Immunoglobulin deposition disease 9800/3 Leukemia, NOS 9801/3 Acute leukemia, NOS 9805/3 Acute biphenotypic leukemia 9820/3 Lymphoid leukemia, NOS 9823/3 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (see also M-9670/3) 9826/3 Burkitt cell leukemia (see also M-9687/3) 9827/3 Adult T-cell leukemia/lymphoma (HTLV-1 positive) Includes all variants 9831/1 T-cell large granular lymphocytic leukemia 9832/3 Prolymphocytic leukemia, NOS 9833/3 Prolymphocytic leukemia, B-cell type 9834/3 Prolymphocytic leukemia, T-cell type 9835/3 Precursor cell lymphoblastic leukemia, NOS (see also M-9727/3) 9836/3 Precursor B-cell lymphoblastic leukemia (see also M-9728/3) 9837/3 Precursor T-cell lymphoblastic leukemia (see also M-9729/3) 9840/3 Acute myeloid leukemia, M6 type 9860/3 Myeloid leukemia, NOS 9861/3 Acute myeloid leukemia, NOS (FAB or WHO type not specified) (see also M-9930/3) 9863/3 Chronic myeloid leukemia, NOS 9866/3 Acute promyelocytic leukemia, t(15;17)(q22;q11-12) 9867/3 Acute myelomonocytic leukemia 9870/3 Acute basophilic leukemia 9871/3 Acute myeloid leukemia with abnormal marrow eosinophils Includes all variants 9872/3 Acute myeloid leukemia, minimal differentiation 9873/3 Acute myeloid leukemia without maturation 9874/3 Acute myeloid leukemia with maturation 9875/3 Chronic myelogenous leukemia, BCR/ABL positive 9876/3 Atypical chronic myeloid leukemia, BCR/ABL negative 9891/3 Acute monocytic leukemia 9895/3 Acute myeloid leukemia with multilineage dysplasia 9896/3 Acute myeloid leukemia, t(8;21)(q22;q22) 9897/3 Acute myeloid leukemia, 11q23 abnormalities 9910/3 Acute megakaryoblastic leukemia 9920/3 Therapy-related acute myeloid leukemia, NOS 9930/3 Myeloid sarcoma (see also M-9861/3) 9931/3 Acute panmyelosis with myelofibrosis (C42.1) 9940/3 Hairy cell leukemia (C42.1) 9945/3 Chronic myelomonocytic leukemia, NOS 9946/3 Juvenile myelomonocytic leukemia 9948/3 Aggressive NK-cell leukemia 9950/3 Polycythemia vera 9960/3 Chronic myeloproliferative disease, NOS 9961/3 Myelosclerosis with myeloid metaplasia 9962/3 Essential thrombocythemia 9963/3 Chronic neutrophilic leukemia 9964/3 Hypereosinophilic syndrome 9970/1 Lymphoproliferative disorder, NOS 9975/1 Myeloproliferative disease, NOS 9980/3 Refractory anemia 9982/3 Refractory anemia with sideroblasts 9983/3 Refractory anemia with excess blasts 9984/3 Refractory anemia with excess blasts in transformation [obs] 9985/3 Refractory cytopenia with multilineage dysplasia 9986/3 Myelodysplastic syndrome with 5q deletion (5q-) syndrome 9987/3 Therapy-related myelodysplastic syndrome, NOS 9989/3 Myelodysplastic syndrome, NOS &commonstageprostatetnm7; AJCC TNM 6 Stage T N M Stage T0 N0 M0 ERROR T0 N1 M0 IV T0 NX M0 UNK T0 N0 M1NOS IV T0 N0 M1a IV T0 N0 M1b IV T0 N0 M1c IV T0 N1 M1NOS IV T0 N1 M1a IV T0 N1 M1b IV T0 N1 M1c IV T0 NX M1NOS IV T0 NX M1a IV T0 NX M1b IV T0 NX M1c IV T0 N0 MX UNK T0 N1 MX IV T0 NX MX UNK T1NOS N1 M0 IV T1NOS NX M0 UNK T1NOS N0 M0 II T1NOS N0 M1NOS IV T1NOS N0 M1a IV T1NOS N0 M1b IV T1NOS N0 M1c IV T1NOS N1 M1NOS IV T1NOS N1 M1a IV T1NOS N1 M1b IV T1NOS N1 M1c IV T1NOS NX M1NOS IV T1NOS NX M1a IV T1NOS NX M1b IV T1NOS NX M1c IV T1NOS N0 MX UNK T1NOS N1 MX IV T1NOS NX MX UNK T1a N0 M0 * T1a N1 M0 IV T1a NX M0 UNK T1a N0 M1NOS IV T1a N0 M1a IV T1a N0 M1b IV T1a N0 M1c IV T1a N1 M1NOS IV T1a N1 M1a IV T1a N1 M1b IV T1a N1 M1c IV T1a NX M1NOS IV T1a NX M1a IV T1a NX M1b IV T1a NX M1c IV T1a N0 MX UNK T1a N1 MX IV T1a NX MX UNK T1b N0 M0 II T1b N1 M0 IV T1b NX M0 UNK T1b N0 M1NOS IV T1b N0 M1a IV T1b N0 M1b IV T1b N0 M1c IV T1b N1 M1NOS IV T1b N1 M1a IV T1b N1 M1b IV T1b N1 M1c IV T1b NX M1NOS IV T1b NX M1a IV T1b NX M1b IV T1b NX M1c IV T1b N0 MX UNK T1b N1 MX IV T1b NX MX UNK T1c N0 M0 II T1c N1 M0 IV T1c NX M0 UNK T1c N0 M1NOS IV T1c N0 M1a IV T1c N0 M1b IV T1c N0 M1c IV T1c N1 M1NOS IV T1c N1 M1a IV T1c N1 M1b IV T1c N1 M1c IV T1c NX M1NOS IV T1c NX M1a IV T1c NX M1b IV T1c NX M1c IV T1c N0 MX UNK T1c N1 MX IV T1c NX MX UNK T2NOS N0 M0 II T2NOS N1 M0 IV T2NOS NX M0 UNK T2NOS N0 M1NOS IV T2NOS N0 M1a IV T2NOS N0 M1b IV T2NOS N0 M1c IV T2NOS N1 M1NOS IV T2NOS N1 M1a IV T2NOS N1 M1b IV T2NOS N1 M1c IV T2NOS NX M1NOS IV T2NOS NX M1a IV T2NOS NX M1b IV T2NOS NX M1c IV T2NOS N0 MX UNK T2NOS N1 MX IV T2NOS NX MX UNK T2a N0 M0 II T2a N1 M0 IV T2a NX M0 UNK T2a N0 M1NOS IV T2a N0 M1a IV T2a N0 M1b IV T2a N0 M1c IV T2a N1 M1NOS IV T2a N1 M1a IV T2a N1 M1b IV T2a N1 M1c IV T2a NX M1NOS IV T2a NX M1a IV T2a NX M1b IV T2a NX M1c IV T2a N0 MX UNK T2a N1 MX IV T2a NX MX UNK T2b N0 M0 II T2b N1 M0 IV T2b NX M0 UNK T2b N0 M1NOS IV T2b N0 M1a IV T2b N0 M1b IV T2b N0 M1c IV T2b N1 M1NOS IV T2b N1 M1a IV T2b N1 M1b IV T2b N1 M1c IV T2b NX M1NOS IV T2b NX M1a IV T2b NX M1b IV T2b NX M1c IV T2b N0 MX UNK T2b N1 MX IV T2b NX MX UNK T2c N0 M0 II T2c N1 M0 IV T2c NX M0 UNK T2c N0 M1NOS IV T2c N0 M1a IV T2c N0 M1b IV T2c N0 M1c IV T2c N1 M1NOS IV T2c N1 M1a IV T2c N1 M1b IV T2c N1 M1c IV T2c NX M1NOS IV T2c NX M1a IV T2c NX M1b IV T2c NX M1c IV T2c N0 MX UNK T2c N1 MX IV T2c NX MX UNK T3NOS N0 M0 III T3NOS N1 M0 IV T3NOS NX M0 UNK T3NOS N0 M1NOS IV T3NOS N0 M1a IV T3NOS N0 M1b IV T3NOS N0 M1c IV T3NOS N1 M1NOS IV T3NOS N1 M1a IV T3NOS N1 M1b IV T3NOS N1 M1c IV T3NOS NX M1NOS IV T3NOS NX M1a IV T3NOS NX M1b IV T3NOS NX M1c IV T3NOS N0 MX UNK T3NOS N1 MX IV T3NOS NX MX UNK T3a N0 M0 III T3a N1 M0 IV T3a NX M0 UNK T3a N0 M1NOS IV T3a N0 M1a IV T3a N0 M1b IV T3a N0 M1c IV T3a N1 M1NOS IV T3a N1 M1a IV T3a N1 M1b IV T3a N1 M1c IV T3a NX M1NOS IV T3a NX M1a IV T3a NX M1b IV T3a NX M1c IV T3a N0 MX UNK T3a N1 MX IV T3a NX MX UNK T3b N0 M0 III T3b N1 M0 IV T3b NX M0 UNK T3b N0 M1NOS IV T3b N0 M1a IV T3b N0 M1b IV T3b N0 M1c IV T3b N1 M1NOS IV T3b N1 M1a IV T3b N1 M1b IV T3b N1 M1c IV T3b NX M1NOS IV T3b NX M1a IV T3b NX M1b IV T3b NX M1c IV T3b N0 MX UNK T3b N1 MX IV T3b NX MX UNK T4 N0 M0 IV T4 N1 M0 IV T4 NX M0 IV T4 N0 M1NOS IV T4 N0 M1a IV T4 N0 M1b IV T4 N0 M1c IV T4 N1 M1NOS IV T4 N1 M1a IV T4 N1 M1b IV T4 N1 M1c IV T4 NX M1NOS IV T4 NX M1a IV T4 NX M1b IV T4 NX M1c IV T4 N0 MX IV T4 N1 MX IV T4 NX MX IV TX N0 M0 UNK TX N1 M0 IV TX NX M0 UNK TX N0 M1NOS IV TX N0 M1a IV TX N0 M1b IV TX N0 M1c IV TX N1 M1NOS IV TX N1 M1a IV TX N1 M1b IV TX N1 M1c IV TX NX M1NOS IV TX NX M1a IV TX NX M1b IV TX NX M1c IV TX N0 MX UNK TX N1 MX IV TX NX MX UNK * For T1a N0 M0, stage is based on grade as follows: if grade is 1, stage is I; if grade is 2, 3, or 4, stage is II; if grade is 9, stage is UNK. &commonsummarystage; Special Calculation Table for SEER Summary Stage Note: Based on the values coded in CS Extension - Clinical Extension and CS Site-Specific Factor 3, CS Extension - Pathologic Extension, SEER Summary Stage is taken from the field indicated in the table below. CS Extension CS SSF 3 000 0 CS SSF 3 020-099 20 99 CS SSF 3 200-750 200 750 CS SSF 3 950-990 950 990 000 SSF3 ERROR CS SSF 3 CS Extension 100-300 CS Extension ERROR CS SSF 3 CS Extension 310-340 ERROR ERROR ERROR ERROR 410-750 CS Extension ERROR CS SSF 3 CS Extension 950-999 SSF3 ERROR CS SSF 3 CS Extension Special Calculation Table for TNM 6 Non-Invasive Pathologic Extension Note: For CS Site-Specific Factor 3 (CS Extension - Pathologic Extension) code 000, based on the value coded in CS Extension - Clinical Extension, the T category mapping and T descriptor for AJCC 6 are taken from the fields indicated in the table below. If the CS Tumor Size/Ext Eval code is invalid, an error is returned and no stage is calculated. CS Extension CS SSF 3 000 0 000 100-300 310-340 ERROR 410-750 950-999 Special Calculation Table for TNM 6 Invasive/Unknown Pathologic Extension Eval Note: For CS Site-Specific Factor 3 (CS Extension - Pathologic Extension) codes 200-990, based on the values coded in CS Tumor Size/Ext Eval and CS Site-Specific Factor 3 (CS Extension - Pathologic Extension), the T category mapping and T descriptor for AJCC 6 staging are taken from the fields indicated in the table below. If the CS Tumor Size/Ext Eval code is invalid, an error is returned and no stage is calculated. CS TS/Ext Eval CS SSF 3 020-099 20 99 CS SSF 3 200-750 200 750 CS SSF 3 950 CS SSF 3 960-980, 990 CS SSF 3 985 0 ERROR 1 ERROR 2 ERROR 3 ERROR 4 ERROR 5 ERROR 6 ERROR 8 ERROR 9 ERROR Blank ERROR * Edit error - The combination of CS Tumor Size/Ext Eval code and CS Site-Specific Factor 3 code in this cell is in error. Special Calculation Table for TNM 7 Non-Invasive Pathologic Extension Note: For CS Site-Specific Factor 3 (CS Extension - Pathologic Extension) code 000, based on the value coded in CS Extension - Clinical Extension, the T category mapping and T descriptor for AJCC 7 staging are taken from the fields indicated in the table below. If the CS Tumor Size/Ext Eval code is invalid, an error is returned and no stage is calculated. CS Extension CS SSF3 000 0 000 100-300 310-340 ERROR 410-750 950-999 Special Calculation Table for TNM 7 Invasive/Unknown Pathologic Extension Eval Note: For CS Site-Specific Factor 3 (CS Extension - Pathologic Extension) codes 200-990, based on the values coded in CS Tumor Size/Ext Eval and Site-Specific Factor 3 (CS Extension - Pathologic Extension), the T category mapping and T descriptor for AJCC 7 staging are taken from the fields indicated in the table below. If the CS Tumor Size/Ext Eval code is invalid, an error is returned and no stage is calculated. CS TS/Ext Eval CS SSF 3 020-099 20 99 CS SSF 3 200-750 200 750 CS SSF 3 950 CS SSF 3 960-980, 990 CS SSF 3 985 0 ERROR 1 ERROR 2 ERROR 3 ERROR 4 ERROR 5 ERROR 6 ERROR 8 ERROR 9 ERROR Blank ERROR * Edit error - The combination of CS Tumor Size/Ext Eval code and CS Site-Specific Factor 3 code in this cell is in error.